AZD8529 Multiple Ascending Dose Study in Healthy Subjects

NCT00765492 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2009-06-26

No results posted yet for this study

Summary

This is a study to evaluate safety, tolerability, PK and PD effects of orally administered AZD8529 after multiple ascending doses

Conditions

  • Healthy Volunteer

Interventions

DRUG

AZD8529

oral

DRUG

Placebo

oral

Sponsors & Collaborators

Principal Investigators

  • Mark Smith, MD, PhD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-10-31
Completion
2009-03-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00765492 on ClinicalTrials.gov